Zinaida Tigay

11 ta ish

Republican Scientific and Practical Centre of Pulmonology and Tuberculosis

1. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

   Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis +15

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyNew England Journal of Medicine20228 iqtibos

   ABIABI:AkademIndex/2022.article.000002

2. Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

   Shona Horter, Beverley Stringer, Jane Greig +5

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyBMC Infectious Diseases20164 iqtibos

   ABIABI:AkademIndex/2016.article.000054

3. Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan

   Shona Horter, Beverley Stringer, Nell Gray +5

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyBMC Infectious Diseases20203 iqtibos

   ABIABI:AkademIndex/2026.other.195708

4. Delay in the diagnosis and treatment of pulmonary tuberculosis in Uzbekistan: a cross-sectional study

   Tatiana Belkina, Doniyor S Khojiev, Mirzagaleb Tillyashaykhov +4

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyBMC Infectious Diseases20141 iqtibos

   ABIABI:AkademIndex/2014.article.000040

5. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan

   Johanna Kuhlin, Chris Smith, Atadjan Khaemraev +8

   MaqolaTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20181 iqtibos

   ABIABI:AkademIndex/2018.article.000181

6. Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

   S. Moe, I. Azamat, Sholpan Allamuratova +14

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyIJTLD OPEN20241 iqtibos

   ABIABI:AkademIndex/2024.article.001030

7. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

   Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyClinical Infectious Diseases20251 iqtibos

   ABIABI:AkademIndex/2025.article.000230

8. Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan

   Philipp du Cros, Atadjan Khamraev, Zinaida Tigay +15

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyERJ Open Research20201 iqtibos

   ABIABI:AkademIndex/2026.other.360284

9. Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, Uzbekistan

   Shona Horter, Jay Achar, Nell Gray +4

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyPLoS ONE20201 iqtibos

   ABIABI:AkademIndex/2026.other.360285

10. Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen

    Jay Achar, Catherine Berry, Krzysztof Herboczek +7

    BoshqaOAOchiq kirishTuberculosis Research and EpidemiologyEmerging infectious diseases20150 iqtibos

    ABIABI:AkademIndex/2015.other.000001

11. Early cardiac safety of the 9-11 month Short course regimen for MDR-TB treatment

    Catherine Berry, James McMahon, Bern-Thomas Nyang’wa +5

    MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyInternational Journal of Infectious Diseases20160 iqtibos

    ABIABI:AkademIndex/2016.article.000559